90% of Severely Sick Covid-19 Patients Respond to New Anti-Inflammatory Drug Trial

0
195

Researchers report that ruxolitinib, an anti-inflammatory drug used to treat to a deadly childhood immune disease, effectively reversed respiratory and multi-system inflammation in severely ill COVID-19 patients.

The study, published in the Journal of Allergy and Clinical Immunology, involved 43 patients hospitalized with severe COVID-19 in Wuhan, ChinaPatients taking ruxolitinib,  were randomly selected to receive two daily 5mg oral doses of the drug, plus standard treatment for COVID-19. A randomly selected control group of 21 patients received a placebo along with the standard of care treatment.

“Ruxolitinib recipients had a numerically faster clinical improvement,” study authors write in their report.

“Significant chest CT improvement, a faster recovery from lymphopenia and favorable side-effect profile in ruxolitinib group were encouraging and informative to future trials to test efficacy of ruxolitinib in a larger population.”

Patients treated with ruxolitinib saw a shorter median time to clinical improvement compared to the control group.

Researchers reported that 90 percent of ruxolitinib patients showed CT scan improvement within 14 days, compared with 9 percent of patients from the control group.

Three patients in the control group eventually died of respiratory failure. All the severely ill patients who received ruxolitinib survived.

More clinical testing of the drug is needed. A larger Phase III clinical trial is now testing up to 400 severely ill COVID-19 patients with the drug, and preliminary clinical data from the study is expected during the summer.

“This is the first therapy we know of that appears to work effectively to quiet the cytokine storm and inflammation in severe COVID-19 disease, and there are no significant toxicities to patients who take the drug by two pills a day,” states Gang Huang, PhD, co-investigator at the Cincinnati Children’s HLH Center of Excellence and the Cancer and Blood Diseases Institute. “This is critical until we can develop and distribute enough effective vaccine to help prevent people from becoming infected.”

Calming the ‘Cytokine Storm’

The cytokine storm that inundates the bodies of severely ill COVID-19 patients with inflammatory immune cells is a common feature of children battling HLH (hemophagocytic lymphohistiocytosis). Huang, who along with a large portion of the world’s scientific community was busy trying to study and find solutions to COVID-19, noticed this common clinical feature of both illnesses.

He also noticed that severe COVID-19 disease clinical manifestations are very similar to those seen in transgenic laboratory mice created to faithfully mimic human secondary HLH in the lab. That preclinical laboratory research, some of it in collaboration with the researchers in Wuhan, China, helped identify the drug ruxolitinib for treating secondary HLH.

The anti-inflammatory drug is also used to treat other blood diseases including leukemia.

“I approached our research colleagues in Wuhan and explained our observations and recommended this drug be tested to quiet the cytokine storm in the multi-system inflammation in patients with severe COVID-19 disease,” Huang said. “The disease was spreading very rapidly and many people were dying. We believed the existing clinical drug would help save lives. So, we worked to push it forward before there is an effective vaccine for everyone.”

Huang said the work with colleagues in China was completed on a compressed timeframe as scientists around the world went on high alert to battle the pandemic in January. During their work, Huang and researchers in China found other clinical studies involving other diseases where ruxolitinib also had worked well at quieting inflammation, and testing on COVID-19 patients proceeded.

Source: Yang Cao, Jia Wei, Liang Zou, Tiebin Jiang, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology, 2020; DOI: 10.1016/j.jaci.2020.05.019

Submit a comment or feedback about this article: